Redefining Pharmacy Practice for a More Patient-Centered Future

Across diverse areas of pharmacy practice, emerging research and
therapeutic innovation are reshaping both patient care and professional
development. From rethinking internship models to better prepare student
pharmacists to exploring novel treatments such as psilocybin-assisted therapy in
palliative care and advancing precision medicine approaches, these developments highlight a broader shift toward more targeted, patient-centered care, which is crucial in all pharmacy spaces.

A peer-reviewed study of University of Arizona pharmacy interns found that job satisfaction and perceived readiness are highest when internships align
with pharmacist-level responsibilities, such as patient counseling and vaccine
administration, rather than primarily technician-level tasks. Survey results showed that mentorship, fair compensation, and opportunities for clinical engagement significantly improve both satisfaction and confidence, while many interns reported feeling underprepared due to limited exposure to real-world pharmacist duties. These findings emphasize the need to redesign pharmacy internships as structured, longitudinal, competency-based experiences that emphasize clinical skill development, mentorship, and progressive responsibility to better prepare students for modern practice.

Psilocybin-assisted therapy is raising interest as a potential tool in palliative care, where current treatments for psychological distress often fall short due to delayed onset and limited effectiveness. Evidence suggests that when used in controlled therapeutic settings, psilocybin can produce rapid, sustained improvements in depression, anxiety, and end-of-life distress with a favorable safety profile; however, access in the US remains highly restricted due to its Schedule I classification, despite regulatory pathways such as the FDA’s expanded access program and the Right to Try Act. There is a need for legislative reform and collaborative efforts among policy makers, clinicians, and pharmacists to create safe, accessible pathways for investigational therapies in palliative care.

The management of obstructive hypertrophic cardiomyopathy (oHCM) is shifting toward precision medicine, with cardiac myosin inhibitors transforming care by targeting underlying disease mechanisms rather than just symptoms. Two experts highlight the importance of distinguishing oHCM from nonobstructive forms to guide therapy, particularly as mavacamten has become a first-line option with evidence for improving symptoms and cardiac structure and reducing the need for invasive procedures. Newer agents, such as aficamten, offer additional flexibility in select cases, though long-term data are still emerging.

These reflect a profession in transition—one that is increasingly focused on innovation, clinical alignment, and patient-centered outcomes. Pharmacists are playing a critical role in shaping the future of care through continued collaboration, education, and system-level change, which is needed to ensure that both patients and health care professionals are prepared for what lies ahead.